Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: A population‐based claims data analysis

Augustin, Matthias; Garbe, C.; Hagenström, Kristina; Petersen, J.; Pereira, Manuel P.; Ständer, Sonja

doi:10.1111/jdv.17485

Cited by 24 publications

(59 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the current data, the estimated annual prevalence of PN in Korea is 4.82 cases per 1000 dermatology outpatients. Considering that our population is limited to dermatology outpatients, it is understandable that the number is higher than the nationwide annual prevalence of PN reported from Poland (6.52 cases per 100,000 population) [ 8 ], Germany (40 cases per 100,000 population) [ 9 ], and the US (72 cases per 100,000 population) [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

“…PN was assigned a distinct International Classification of Diseases, 10th Revision (ICD-10) code in 2015 [ 6 , 7 ]. To date, the United States (US), Poland, and Germany have reported nationwide annual prevalence of PN with values of 6.52 (Poland) [ 8 ], 40 (Germany) [ 9 ], and 72 (US) [ 10 ] per 100,000 people. Ethnic differences likely exist, with PN disproportionately affecting African Americans [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology, Comorbidities, and Prescription Patterns of Korean Prurigo Nodularis Patients: A Multi-Institution Study

Woo

Wang

Sohn

et al. 2021

JCM

View full text Add to dashboard Cite

Prurigo nodularis (PN) is a chronic dermatosis typified by extraordinarily itchy nodules. However, little is known of the nature and extent of PN in Asian people. This study aimed to describe the epidemiology, comorbidities, and prescription pattern of PN in Koreans based on a large dermatology outpatient cohort. Patients with PN were identified from the Catholic Medical Center (CMC) clinical data warehouse. Anonymized data on age, sex, diagnostic codes, prescriptions, visitation dates, and other relevant parameters were collected. Pearson correlation analysis was used to calculate the correlation between PN prevalence and patient age. Conditional logistic regression modeling was adopted to measure the comorbidity risk of PN. A total of 3591 patients with PN were identified at the Catholic Medical Center Health System dermatology outpatient clinic in the period 2007–2020. A comparison of the study patients with age- and sex-matched controls (dermatology outpatients without PN) indicated that PN was associated with various comorbidities including chronic kidney disease (adjusted odds ratio (aOR), 1.48; 95% confidence interval (CI), 1.29–1.70), dyslipidemia (aOR, 1.88; 95% CI, 1.56–2.27), type 2 diabetes mellitus (aOR, 1.37; 95% CI, 1.22–1.54), arterial hypertension (aOR, 1.50; 95% CI, 1.30–1.73), autoimmune thyroiditis (aOR, 2.43; 95% CI, 1.42–4.16), non-Hodgkin’s lymphoma (aOR, 1.95; 95% CI, 1.23–3.07), and atopic dermatitis (aOR, 2.16, 95% CI, 1.91–2.45). Regarding prescription patterns, topical steroids were most favored, followed by topical calcineurin inhibitors; oral antihistamines were the most preferred systemic agent for PN. PN is a relatively rare but significant disease among Korean dermatology outpatients with a high comorbidity burden compared to dermatology outpatients without PN. There is great need for breakthroughs in PN treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Epidemiology, Comorbidities, and Prescription Patterns of Korean Prurigo Nodularis Patients: A Multi-Institution Study

Woo

Wang

Sohn

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…For this, we used secondary data analyses based on routine data from the statutory health insurance company DAK-Gesundheit for 2010, which are considered to be representative of the average German population. In a previous analysis in this population of German adults, we determined the sex- and age-adjusted prevalence of prurigo to be 0.19%, while the adjusted prevalence of pruritus was 2.14% [11].…”

Section: Discussionmentioning

confidence: 99%

Healthcare Utilization and Treatment Patterns in Patients with Chronic Prurigo and Chronic Pruritus in Germany

Ständer¹,

Garbe²,

Hagenström³

et al. 2022

Dermatology

Self Cite

View full text Add to dashboard Cite

Background: To date, there have been no large studies describing real-world treatment of chronic prurigo (CPG) and pruritus (CPR) in Germany. Objective: To determine the healthcare utilization, treatment patterns, and costs associated with CPG and CPR in Germany. Methods: Retrospective analysis using anonymized claims data (German DAK-Gesundheit), based on a 40% sample of all insured adults of the DAK-Gesundheit on December 31, 2010 (N = 2,006,003). Results: Patients with CPR (prevalence 2.2%) most commonly visited general medicine/general practitioners (GPs, 80.1%), followed by gynecologists (66.1%) and dermatologists (51.1%). Patients with CPG (prevalence 0.2%) most commonly visited dermatologists (85.7%), GPs (78.1%), and ophthalmologists (47.2%). Of adult patients, 44% received at least one drug prescription. Two thirds of patients with a drug prescription received ≥1 topical drug (66.2%), and 54.3% ≥1 systemic drug (total costs of approximately EUR 550,000 and 2,500,000, respectively). Of patients with CPG, 33.8% received ≥1 systemic and 45.1% ≥1 topical drug prescription (costs of approximately EUR 360,000 vs. 105,000). Of patients with CPR, 23.5% received ≥1 systemic and 28.6% ≥1 topical drug prescription (costs of approximately EUR 2,000,000 vs. 500,000). Of patients with CPG, 5.8% received ≥1 phototherapy application vs. 1.2% of patients with CPR. Conclusions: These findings reflect the reality of care and can form a basis for the identification of overuse, underuse, and misuse in order to design CPG and CPR healthcare more effectively and efficiently.

show abstract

“…Children may be affected, but this is very rare. Epidemiological studies are infrequent and report different prevalences depending on the method and population included ( 13 , 91 , 92 ). For example, Poland reported an estimated prevalence of 6.5/100,000, USA of 36.7 to 43.9/100,000 and Germany up to 100/100,000.…”

Section: Chronic Inflammatory Skin Diseasesmentioning

confidence: 99%

Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases

et al. 2022

View full text Add to dashboard Cite

An estimated 20–25% of the population is affected by chronic, non-communicable inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most frequent chronic inflammatory skin diseases are atopic dermatitis, psoriasis, urticaria, lichen planus, and hidradenitis suppurativa, driven by a complex interplay of genetics and environmental factors. Autoimmunity is another important cause of chronic skin inflammation. The autoimmune response may be mainly T cell driven, such as in alopecia areata or vitiligo, or B cell driven in chronic spontaneous urticaria, pemphigus and pemphigoid diseases. Rare causes of chronic skin inflammation are autoinflammatory diseases, or rheumatic diseases, such as cutaneous lupus erythematosus or dermatomyositis. Whilst we have seen a significant improvement in diagnosis and treatment, several challenges remain. Especially for rarer causes of chronic skin inflammation, early diagnosis is often missed because of low awareness and lack of diagnostics. Systemic immunosuppression is the treatment of choice for almost all of these diseases. Adverse events due to immunosuppression, insufficient therapeutic responses and relapses remain a challenge. For atopic dermatitis and psoriasis, a broad spectrum of innovative treatments has been developed. However, treatment responses cannot be predicted so far. Hence, development of (bio)markers allowing selection of specific medications for individual patients is needed. Given the encouraging developments during the past years, we envision that many of these challenges in the diagnosis and treatment of chronic inflammatory skin diseases will be thoroughly addressed in the future.

show abstract

Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: A population‐based claims data analysis

Cited by 24 publications

References 16 publications

Epidemiology, Comorbidities, and Prescription Patterns of Korean Prurigo Nodularis Patients: A Multi-Institution Study

Epidemiology, Comorbidities, and Prescription Patterns of Korean Prurigo Nodularis Patients: A Multi-Institution Study

Healthcare Utilization and Treatment Patterns in Patients with Chronic Prurigo and Chronic Pruritus in Germany

Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases

Contact Info

Product

Resources

About